sponsored
PatientsVille.com Logo

PatientsVille

Novorapid Medical Research Studies

Up-to-date List of Novorapid Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Novorapid Medical Research Studies

Rank Status Study
1 Recruiting A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
Conditions: Diabetes;   Diabetes Mellitus, Type 1
Interventions: Drug: insulin degludec/insulin aspart;   Drug: insulin aspart;   Drug: insulin detemir
Outcome Measures: Change from baseline in HbA1c (glycosylated haemoglobin) (%);   Change from baseline in fasting plasma glucose;   Incidence of treatment emergent adverse events (TEAEs);   Number of treatment emergent confirmed hypoglycaemic episodes (plasma glucose (PG) below 3.1 mmol/L (56 mg/dL) or severe hypoglycaemia);   Number of treatment emergent nocturnal confirmed hypoglycaemic episodes;   Number of hyperglycaemic episodes (PG above 14.0 mmol/L (250 mg/dL) where subject looks/feels ill;   Number of hyperglycaemic episodes (PG above 14.0 mmol/L (250 mg/dL) where subject looks/feels ill with ketosis (blood ketones above 1.5 mmol/L)
2 Recruiting A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes
Conditions: Diabetes;   Diabetes Mellitus, Type 1
Interventions: Drug: Faster-acting insulin aspart;   Drug: insulin aspart
Outcome Measures: Mean plasma glucose concentration;   Area under the serum insulin aspart concentration-time curve
3 Recruiting A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes
Conditions: Diabetes;   Diabetes Mellitus, Type 1
Interventions: Drug: insulin aspart (faster acting insulin aspart);   Drug: insulin aspart
Outcome Measures: Area under the glucose infusion rate curve;   Area under the serum insulin aspart concentration-time curve;   Maximum glucose infusion rate;   Maximum observed serum insulin aspart concentration
4 Recruiting A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects
Conditions: Diabetes;   Healthy
Intervention: Drug: insulin aspart (faster acting insulin aspart)
Outcome Measures: Area under the serum insulin aspart concentration-time curve (only for subcutaneous administration);   Area under the serum insulin aspart concentration-time curve (only for intramuscular administration);   Maximum observed serum insulin aspart concentration (only for subcutaneous and intramuscular administration)
5 Recruiting Insulin by Jet-injection for Hyperglycemia in Diabetes
Condition: Diabetes Mellitus
Intervention: Drug: insulin aspart
Outcome Measures: T-BG≥10;   T-BG5 and 8 (min);   Rfall;   BG-AUC 0-2h;   BG-AUC 0-6h;   C-INSmax (pmol/l);   T-INSmax;   T-INSBL;   INSAUC;   T-INSAUC50%
6 Not yet recruiting The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
Conditions: Diabetes Mellitus, Type 2;   Diabetes
Interventions: Drug: Metformin;   Drug: Detemir;   Drug: Liraglutide;   Drug: Insulin Aspart
Outcome Measures: Composite end-point;   Mean change from randomization in A1c at week 26;   Percentage of patients reaching target A1c of <7% at week 26;   Percentage of patients reaching pre-specified "treatment failure" outcome;   Mean change from randomization in body weight;   Percentage of patients who lost 5% or more of body weight from randomization;   Hypoglycemic episodes;   Percentage of patients experiencing any hypoglycemic episode;   Diabetes Quality of Life (DQOL)questionnaire score;   Short Form-36 (SF-36) questionnaire score;   Number of daily injections;   Health care cost, total;   Health care cost, diabetes-related;   Number of titration events by healthcare professional;   Number of titration events by patient;   Healthcare provider time during scheduled office (minutes/visit);   Healthcare provider time, unscheduled (total minutes);   Compliance with pharmacologic therapy;   Change in LDL cholesterol from baseline to week 26;   Change in triglycerides from baseline;   7-point glucose profiles over 2 consecutive days
7 Recruiting A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide;   Drug: insulin aspart
Outcome Measures: Change from baseline in HbA1c (glycosylated haemoglobin);   Change from baseline in body weight;   Number of treatment-emergent confirmed hypoglycaemic episodes
8 Recruiting A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes
Conditions: Diabetes;   Diabetes Mellitus, Type 1
Interventions: Drug: insulin aspart (FIAsp);   Drug: insulin aspart
Outcome Measures: Area under the serum insulin aspart concentration-time curve;   Maximum observed serum insulin aspart concentration
9 Recruiting Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia
Condition: Post-Transplant Glucocorticoid Induced Diabetes
Interventions: Drug: Neutral protamine hagedorn (NPH) insulin;   Drug: Regular human insulin or Insulin Aspart;   Drug: Insulin glargine
Outcome Measures: Blood glucose - inpatient;   Post prandial blood glucose - inpatient;   Length of inpatient hospital stay;   Blood glucose;   Hemoglobin A1C;   Post prandial blood glucose;   Hypoglycemic episodes;   Glycemic treatment failure;   Cardiovascular events;   Post-transplant infections or new antibiotic use;   Transplant graft failure;   New acute renal failure;   Mortality
10 Recruiting A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes
Conditions: Diabetes;   Diabetes Mellitus, Type 1
Interventions: Drug: insulin degludec;   Drug: insulin glargine;   Drug: insulin aspart
Outcome Measures: Number of treatment emergent severe or BG (blood glucose) confirmed symptomatic hypoglycaemic episodes during the maintenance period;   Number of treatment emergent severe or BG confirmed symptomatic nocturnal hypoglycaemic episodes during the maintenance period;   Proportion of subjects with one or more severe hypoglycaemic episodes during the maintenance period;   Incidence of treatment emergent adverse events;   Change from baseline in HbA1c (glycosylated haemoglobin);   FPG (Fasting plasma glucose)
11 Recruiting Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Insulin glulisine;   Drug: Insulin aspart
Outcome Measures: Postprandial glycemia;   Hypoglycemia episodes;   Glucose Area Under the Curve (AUC);   Mean amplitude of glycemic excursion (MAGE);   Difference between the maximum and baseline glycemia
12 Unknown  Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin
Condition: Type 2 Diabetes
Intervention: Drug: Levemir (Detemir) and Novolog (Aspart) Insulin
Outcome Measures: Length of Hospitalization Stay;   Cost of Hospitalization;   All-Cause Mortality;   Frequency of Hypoglycemic Episodes;   Rate of Transfer to Telemetry Unity;   Rate of Nosocomial Infections;   Rate of Surgical Procedures;   Rate of Re-hospitalization;   Time to goal blood glucose level;   Time to becoming medically stable for discharge
13 Recruiting Point-of-Care Glucose Testing and Insulin Supplementation
Condition: Diabetes
Intervention: Drug: hs insulin Aspart (Novolog)
Outcome Measures: mean fasting blood glucose;   mean daily BG and number of BG within target;   Number of hypoglycemia (BG < 70 mg/dl) and severe hyperglycemia (BG>300 mg/dl);   Daily dose of insulin;   Length of hospital stay;   Hospital Mortality;   Nosocomial infections (CDC);   Pneumonia;   Bacteremia;   participants will be followed for the duration of hospital stay, an expected average of 6 days;   Acute renal failure [rise >50% of baseline or creatinine >2.5 mg/dl]
14 Recruiting Cardiac Surgery Neuroprotection Study in Elders
Conditions: Post-operative Cognitive Decline;   Post-operative Delirium
Interventions: Drug: Aspart insulin;   Drug: Placebo
Outcome Measures: Change from baseline cognitive function;   Delirium and Coma Free Days;   Association between post-operative delirium and post-operative cognitive decline;   Hypoglycemia;   Nasal irritation;   Survival;   ICU length of stay;   Hospital length of stay
15 Unknown  Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA)
Condition: Latent Autoimmune Diabetes in Adults LADA
Interventions: Drug: NovoMix 30;   Drug: Tablet treatment
Outcome Measures: Change in fasting serum C-peptide level over 24 months and (2) change in HbA1c level over 24 months in patients with LADA.;   Hypoglycaemic events
16 Recruiting Mechanisms of Insulin Facilitation of Memory
Conditions: Memory;   Insulin
Intervention: Drug: NovoLog Insulin
Outcome Measures: cerebral glutamate concentration;   cognitive performance
17 Unknown  Treatment of Impaired Glucose Tolerance in Pregnancy
Conditions: Impaired Glucose Tolerance;   Fetal Macrosomia
Intervention: Drug: Insulin aspart and Insulin human (isophane)
Outcome Measures: Perinatal morbidity and intrauterine growth;   Children´s future health
18 Recruiting Post-Gastric Bypass Hypoglycemia
Condition: Hyperinsulinemic Hypoglycemia
Interventions: Other: high carbohydrate test meal;   Other: high carbohydrate test meal after pre-treatment with rapid acting aspart insulin;   Other: high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal
Outcome Measure: The primary study endpoint will be occurrence or not of plasma glucose < 60 mg/dL during the 4 hours after the test meal (binary endpoint).
19 Recruiting Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 30
Outcome Measures: Change in HbA1c from baseline;   Change in fasting plasma glucose (FPG) (laboratory values) from baseline;   Number of hypoglycaemic episodes during the trial from baseline;   Change in Patient Reported Outcomes: Treatment-Related Impact Measures for Diabetes (TRIM-D)
20 Recruiting A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: MK-1293;   Drug: Lantus™;   Drug: Novolog™
Outcome Measures: Pharmacodynamics (PD): Duration of Pharmacodynamic Action;   PD: Area Under the Glucose Infusion Rate Versus Time Curve Over 24 Hours After Dosing (GIR-AUC0-24hr);   PD: Area Under the Glucose Infusion Rate Versus Time Curve Over the First 12 Hours After Dosing (GIR-AUC0-12hr);   PD: Area Under the Glucose Infusion Rate Versus Time Curve Over the Second 12 Hours After Dosing (GIR-AUC12-24hr);   PD: Maximum Glucose Infusion Rate (GIRmax);   Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC0-24);   PK: Maximum Plasma Concentration (Cmax);   PK: Area Under the Plasma Concentration Versus Time Curve Over the First 12 Hours After Dosing (AUC0-12);   PK: Area Under the Plasma Concentration Versus Time Curve Over the Second 12 Hours After Dosing (AUC12-24)

These studies may lead to new treatments and are adding insight into Novorapid etiology and treatment.

A major focus of Novorapid research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Novorapid